Advocacy

President's Column | February 2026

I’m writing this month’s newsletter as we sit under a -20° windchill here in the Midwest, while much of the rest of the country is buried under feet of snow. At this point, it’s officially “too cold to snow” in Wisconsin—something I’m still not sure is good news or bad news. And as we brace for yet another round of winter weather, I can’t help but think of Groundhog Day… because let’s be honest, some of our clinic days can feel a little like that too.

SDPA Statement on Topical Steroids

The Society of Dermatology Physician Assistants (SDPA) recognizes emerging evidence on potential adverse effects associated with prolonged topical corticosteroid use in managing chronic inflammatory dermatoses. These findings highlight the need for vigilant treatment planning to mitigate long-term risks. To prioritize patient safety and optimize outcomes, the SDPA advocates for routine assessment of cumulative steroid exposure as a cornerstone of patient care.

From the Hill: What the One Big Beautiful Bill Act Means for Dermatology PAs

Washington recently passed the wide-ranging One Big Beautiful Bill Act, a sweeping legislative package that touches everything from energy to tax reform.

Apremilast and IRA

The IRA’s drug price negotiations aim to lower costs but risk limiting patient access, treatment options, and future innovation. The SDPA urges policymakers to balance affordability with maintaining a broad range of therapies essential for individualized patient care.

Pharmacy Benefit Reform - New York S.1267-A

Pharmacy Benefit Reform Fails in 118th Congress New York S.1267-A Sets Precedent for States Moving Forward